Review
The multifaceted therapeutic potential of benfotiamine

https://doi.org/10.1016/j.phrs.2010.02.008Get rights and content

Abstract

Thiamine, known as vitamin B1, plays an essential role in energy metabolism. Benfotiamine (S-benzoylthiamine O-monophoshate) is a synthetic S-acyl derivative of thiamine. Once absorbed, benfotiamine is dephosphorylated by ecto-alkaline phosphatase to lipid-soluble S-benzoylthiamine. Transketolase is an enzyme that directs the precursors of advanced glycation end products (AGEs) to pentose phosphate pathway. Benfotiamine administration increases the levels of intracellular thiamine diphosphate, a cofactor necessary for the activation transketolase, resulting in the reduction of tissue level of AGEs. The elevated level of AGEs has been implicated in the induction and progression of diabetes-associated complications. Chronic hyperglycemia accelerates the reaction between glucose and proteins leading to the formation of AGEs, which form irreversible cross-links with many macromolecules such as collagen. In diabetes, AGEs accumulate in tissues at an accelerated rate. Experimental studies have elucidated that binding of AGEs to their specific receptors (RAGE) activates mainly monocytes and endothelial cells and consequently induces various inflammatory events. Moreover, AGEs exaggerate the status of oxidative stress in diabetes that may additionally contribute to functional changes in vascular tone control observed in diabetes. The anti-AGE property of benfotiamine certainly makes it effective for the treatment of diabetic neuropathy, nephropathy and retinopathy. Interestingly, few recent studies demonstrated additional non-AGE-dependent pharmacological actions of benfotiamine. The present review critically analyzed the multifaceted therapeutic potential of benfotiamine.

Introduction

Nutritional deficiency is considered to be a major health burden affecting the routine life style of human beings in developing countries. Thiamine is a water-soluble vitamin found mainly in cereals, legumes, dried beans, soybeans, nuts, fortified breads, and lean meats and fish. Thiamine plays a key role in cellular energy metabolism as it helps in the process of conversion of carbohydrates into energy. Thiamine is required for normal functioning of the heart, muscles and nerves, and its intake is beneficial in the treatment of certain metabolic disorders [1], [2]. Benfotiamine is a lipid-soluble thiamine precursor having much higher bioavailability than genuine thiamine [3], [4]. Growing body of evidence revealed that benfotiamine alleviates the severity of diabetic complications such as neuropathy, nephropathy and retinopathy by inhibiting the formation of advanced glycation end products (AGEs) [3], [5], [6]. Benfotiamine prevents the progression of diabetic complications by increasing tissue levels of thiamine diphosphate, which enhances the transketolase activity that directs the precursors of AGEs to pentose phosphate pathway, resulting in the reduction of tissue levels of AGEs [7], [8], [9], [10]. Other beneficial effects of benfotiamine include improvement in cardiomyocyte contractile dysfunction in experimental diabetes mellitus [11], reduction in neuropathic pain [12], [13], [14] and improvement in experimental post-ischaemic healing [15]. Moreover, benfotiamine has been shown to reduce oxidative stress in a mechanism unrelated to its anti-AGE property [4]. In addition to its beneficial effects in preventing the progression of diabetic complications, benfotiamine has been demonstrated to prevent the induction of vascular endothelial dysfunction [9], [16], [17], [18], [19], which suggests the novel role of benfotiamine in improving the vascular functional regulation. Benfotiamine is absorbed in the body better than thiamine and in fact benfotiamine has better bioavailability than thiamine. Although benfotiamine has been shown to be similar to thiamine in correcting endothelial cell defects induced by high glucose [16], thiamine is needed to be administered at high dose as compared to benfotiamine to prevent the diabetic complications [8]. The present review critically discussed the wide array of recently revealed therapeutic potential of benfotiamine.

Section snippets

Pharmacology of benfotiamine

Thiamine-derived compounds were discovered from the plants of Allium genus such as onions, shallots and leeks and named as allithiamines [20]. The most effective compound of allithiamine family having the anti-AGEs property was subsequently identified and named as benfotiamine. The benfotiamine is a lipid-soluble congener of thiamine having a unique open thiazole-ringed structure that enables it to enter directly through the cell membrane resulting in enhanced bioavailability [21], [22], [23].

Formation of AGE products and their pathological implications: a fleeting look

Nonenzymatic protein glycation by glucose is a complex cascade of reactions yielding a heterogeneous class of compounds, collectively termed as AGEs. The AGEs are formed by nonenzymatic reaction between reducing sugars and amino acids on proteins, lipids and nucleic acids (Fig. 2). There are two major pathways in which AGEs can be formed in the biological system. One way is through a simple series of chemical reactions known as Maillard pathway (Fig. 3). The Maillard reaction begins with the

AGE-dependent and -independent pharmacological actions of benfotiamine

Benfotiamine, an inhibitor of the formation of AGEs, exerts its beneficial effects through a diverse mechanism. In diabetes, benfotiamine blocks three major biochemical pathways implicated in the pathogenesis of chronic hyperglycemia-induced vascular damage, i.e., hexosamine pathway, AGE formation pathway and diacylglycerol (DAG)–protein kinase C (PKC) pathway, which are activated by the high availability of the glycolytic metabolites such as glyceraldehyde-3-phosphate and fructose-6-phosphate

Novel therapeutic role of benfotiamine

Benfotiamine possesses much higher bioavailability than genuine thiamine that may uplift the preference of benfotiamine instead of thiamine for related therapeutic applications. Benfotiamine counteracts the damaging effects of hyperglycaemia on vascular cells that accounts for its beneficial defensive role in preventing diabetic complications [53]. As stated in previous section, benfotiamine has a therapeutic potential to halt the development of diabetes-induced neuropathy, nephropathy and

Concluding remarks

Benfotiamine has ability to halt the progression of many serious complications of prolonged hyperglycemia that certainly supports its therapeutic applications in diabetic patients. In fact, any bodily function improved by a therapeutic level of thiamine would most likely be enhanced by benfotiamine. The exaggerated benfotiamine consumption as a dietary supplement could over-stimulate the enzyme transketolase, which may account for some serious adverse drug reactions; however, the clear

Conflict of interest

The authors declared no conflict of interest.

Acknowledgment

The authors express their gratitude to Shri. S. Sriram Ashok Ji, B.E., Correspondent, and Shri. P. Dharmar Ji, Secretary of SB College of Pharmacy, Sivakasi, India for their inspiration and constant support to accomplish this study.

References (72)

  • P. Balakumar et al.

    Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions

    Pharmacol Res

    (2009)
  • P. Balakumar et al.

    Vascular endothelial dysfunction: a tug of war in diabetic nephropathy?

    Biomed Pharmacother

    (2009)
  • E. Berrone et al.

    Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose

    J Biol Chem

    (2006)
  • P. Balakumar et al.

    Potential target sites to modulate vascular endothelial dysfunction: current perspectives and future directions

    Toxicology

    (2008)
  • P.J. Thornalley

    The potential role of thiamine (vitamin B(1)) in diabetic complications

    Curr Diab Rev

    (2005)
  • S.A. Malecka et al.

    Prophylactic and therapeutic application of thiamine (vitamin B1)—a new point of view

    Wiad Lek

    (2006)
  • H.P. Hammes et al.

    Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy

    Nat Med

    (2003)
  • H. Stracke et al.

    Efficacy of benfotiamine versus thiamin on function and glycation products of peripheral nerves in diabetic rats

    Exp Clin Endocrinol Diab

    (2001)
  • A. Stirban et al.

    Adiponectin decreases postprandially following a heat-processed meal in individuals with type 2 diabetes: an effect prevented by benfotiamine and cooking method

    Diabetes Care

    (2007)
  • J. Lin et al.

    Benfotiamine inhibits intracellular formation of advanced glycation endproducts in vivo

    Diabetes

    (2000)
  • R. Babaei-Jadidi et al.

    Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine

    Diabetes

    (2003)
  • A. Stirban et al.

    Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes

    Diabetes Care

    (2006)
  • M.L. Volvert et al.

    Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives

    BMC Pharmacol

    (2008)
  • A.F. Ceylan-Isik et al.

    High-dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin-induced diabetes mellitus

    J Appl Physiol

    (2006)
  • H. Woelk et al.

    Benfotiamine in treatment of alcoholic polyneuropathy: an 8-week randomized controlled study (BAP I study)

    Alc Alc

    (1998)
  • G. Winkler et al.

    Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy

    Arzneimittelforschung

    (1999)
  • E. Haupt et al.

    Benfotiamine in the treatment of diabetic polyneuropathy-a three-week randomized, controlled pilot study (BEDIP study)

    Int J Clin Pharmacol Ther

    (2005)
  • S. Gadau et al.

    Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis

    Diabetologia

    (2006)
  • F. Pomero et al.

    Benfotiamine is similar to thiamine in correcting endothelial cell defects induced by high glucose

    Acta Diabetol

    (2001)
  • E. Beltramo et al.

    Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose

    Diab Metab Res Rev

    (2004)
  • P. Balakumar et al.

    Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat

    Mol Cell Biochem

    (2009)
  • M. Fujiwara et al.

    Allithiamine, a newly found derivative of vitamin B1

    J Biochem

    (1954)
  • R. Bitsch et al.

    Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamine derivative

    Ann Nutr Metab

    (1991)
  • D. Loew

    Pharmacokinetics of thiamine derivatives especially of benfotiamine

    Int J Clin Pharmacol Ther

    (1996)
  • U.C.S. Yadav et al.

    Prevention of endotoxin-induced uveitis in rats by benfotiamine, a lipophilic analogue of vitamine B1

    Invest Ophthalmol Vis Sci

    (2009)
  • H. Shindo et al.

    Studies on the absorption of S-benzoylthiamine O-monophosphate. II. Permeability to red cell membranes

    Vitamins

    (1968)
  • Cited by (0)

    View full text